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Introduction
The six transcription factors belonging to the GATA family in mammals play
important roles in mesoderm and endoderm development. GATA1-3, but not
GATA4-6, play critical roles in hematopoiesis.1 Mice deficient for GATA4 show
defects in the heart and intestine and die around embryonic day (E) 13.5.2-4
A mesodermal-specific enhancer of Gata4, called G2, drives Gata4 expression in
the lateral mesoderm and allantois starting at E7.5. Later, this activity is restricted to
the septum transversum and ceases by E12.5.5 Our previous work using G2Cre;R26REYFP
mice has shown that the cell lineage where Gata4 is activated by G2 contributes to
hepatic stellate cells. Inactivation of Gata4 using this G2Cre driver is lethal by midges-
tation. The anemia observed in the G2Cre;Gata4flox/floxembryos was attributed to a fail-
ure in the expansion of the hematopoietic progenitors in the fetal liver. Interestingly,
a small population of hepatic YFP+ cells from G2Cre;R26REYFP embryos was positive for
leukocyte and megakaryocyte markers.6 We have performed a comprehensive analy-
GATA transcription factors are expressed in the mesoderm andendoderm during development. GATA1-3, but not GATA4, arecritically involved in hematopoiesis. An enhancer (G2) of the
mouse Gata4 gene directs its expression throughout the lateral meso-
derm and the allantois, beginning at embryonic day 7.5, becoming
restricted to the septum transversum by embryonic day 10.5, and disap-
pearing by midgestation. We have studied the developmental fate of the
G2-Gata4 cell lineage using a G2-Gata4Cre;R26REYFP mouse line. We found
a substantial number of YFP+ hematopoietic cells of lymphoid, myeloid
and erythroid lineages in embryos. Fetal CD41+/cKit+/CD34+ and
Lin–/cKit+/CD31+ YFP+ hematopoietic progenitors were much more
abundant in the placenta than in the aorta-gonad-mesonephros area.
They were clonogenic in the MethoCult assay and fully reconstituted
hematopoiesis in myeloablated mice. YFP+ cells represented about 20%
of the hematopoietic system of adult mice. Adult YFP+ hematopoietic
stem cells constituted a long-term repopulating, transplantable popula-
tion. Thus, a lineage of adult hematopoietic stem cells is characterized by
the expression of GATA4 in their embryonic progenitors and probably
by its extraembryonic (placental) origin, although GATA4 appeared not
to be required for hematopoietic stem cell differentiation. Both lineages
basically showed similar physiological behavior in normal mice, but clin-
ically relevant properties of this particular hematopoietic stem cell popu-
lation should be checked in physiopathological conditions. 
A population of hematopoietic stem cells
derives from GATA4-expressing progenitors
located in the placenta and lateral mesoderm
of mice
Ana Cañete,1-2 Rita Carmona,1-2 Laura Ariza,1-2 María José Sánchez,3
Anabel Rojas4 and Ramón Muñoz-Chápuli1-2
1Department of Animal Biology, University of Málaga; 2Andalusian Center for
Nanomedicine and Biotechnology (BIONAND), Málaga; 3Centro Andaluz de Biología del
Desarrollo (CABD), Consejo Superior de Investigaciones Científicas (CSIC), Universidad
Pablo de Olavide (UPO), Seville; 4Andalusian Center of Molecular Biology and
Regenerative Medicine (CABIMER) and Centro de Investigación Biomédica en Red de
Diabetes y Enfermedades Metabólicas Asociadas-CIBERDEM, Seville, Spain
ABSTRACT
sis of hematopoietic G2-Gata4 lineage cells in mice. A sig-
nificant fraction of the fetal and adult blood cells derives
from this lineage, despite the short embryonic period in
which the G2 enhancer is active. Thus, the adult
hematopoietic stem cells (HSCs) would belong to two dis-
tinct mesodermal lineages, depending on whether they
derive from progenitors expressing GATA4 under control of
the G2 enhancer or not. This observation raises multiple
questions about the embryonic origin of this lineage, the
hypothetical role played by GATA4 in hematopoiesis or the
existence of different properties of the adult HSCs depend-
ing on their embryonic lineage. Answers to the these ques-
tions have been the aims of the study herein, which has
confirmed the existence of a long-term repopulating adult
HSC population derived from the embryonic G2-Gata4 lin-
eage. The experimental evidence collected suggests that this
hematopoietic lineage has a placental origin, but GATA4
appears dispensable for its differentiation. 
Methods
Transgenic mouse lines
The animals used in our research program were handled in com-
pliance with the institutional and European Union guidelines for
animal care and welfare and housed in the animal facility of the
University of Málaga under controlled standard conditions. The
procedure was approved by the Committee on the Ethics of
Animal Experiments of the University of Malaga (procedure code
2015-0028). Additional animals were maintained in the CABD ani-
mal care facility with the approval of the ethical committee of
CSIC and the University of Pablo de Olavide. All embryos were
staged from the time point of vaginal plug observation, which was
designated as E0.5. 
G2Cre and Gata4 floxed mice were generated as previously
described.5,7 G2Cre mice were crossed with the reporter line
Rosa26REYFP (B6.129X1-Gt(ROSA)26Sortm1(EYFP)Cos/J). The
resulting G2Cre/+;R26REYFP mice constitutively express YFP in all the
lineage of the cells where the enhancer G2 has been activated. The
tamoxifen-inducible Scl-CreERT mouse line was generated by Dr.
Joachim Göthert.8
Blood and tissue samples from embryos and adult mice were
obtained as described in the Online Supplementary Methods. 
RT-PCR
Bone marrow (BM) cells obtained from the femur were washed
in phosphate buffered saline  (PBS) and homogenized in 1mL of Tri
Reagent (Sigma). Aorta-gonad-mesonephros (AGM) and fetal liver
were used as positive controls. Details of reverse transcription-
polymerase chain reaction (RT-PCR) and primer sequences are
shown in the Online Supplementary Methods.
Flow cytometry
Cell suspensions were incubated with fluorochrome-conjugated
antibodies for 30 min on ice. After washing, the labelled cells were
analyzed in a FACSverse flow cytometer. For fluorescence activat-
ed cell sorting, the labelled cells were resuspended in 1 mL of
working solution and sorted in a MoFlo cell sorter. Hoechst 33342
staining of bone marrow cells to identify the side population was
performed according to standard protocols.9 A list of the antibodies
used is shown in the Online Supplementary Table S1.
Colony assay in MethoCult
Cells obtained from tissue homogenization were cultured in the
semisolid medium MethoCult (GF M3434, Stem Cell Technologies
Inc. Vancouver, Canada). Ectoplacental cones together with the
allantois were obtained by fine dissection of E8.0 embryos and
preincubated for 5 days in 24-well multidishes (Nunc). After 7-14
days the colonies were photographed. When the fluorescence of
the cells had to be detected, the colonies were picked and adhered
to a slide via cytospin. More details are provided in the Online
Supplementary Methods.
Adult bone marrow cells transplant into irradiated 
adult mice
2,5 million bone marrow cells were suspended in 300 μL of
Dulbecco’s phosphate buffered saline  (DPBS) +1% fetal calf serum
(FCS) +1% penicillin/streptomycin (P/S) and injected in the tail
vein of C57Bl/6 x CBA irradiated mice as described in the Online
Supplementary Methods. 
Adult bone marrow and embryonic cells transplant 
in newborn mice treated with Busulfan
Busulfan (1, 4-Butanediol dimethanesulfonate, Sigma-Aldrich) is
a myeloablative agent used to improve the efficiency of a
hematopoietic graft in newborn mice.10,11 Pregnant females are
injected by intraperitoneal (i.p.) injection on days 17 and 18 of ges-
tation with a 15 mg busulfan/Kg dose. Newborns at stage P1 are
injected through the facial vein with cells suspended in 50 μL of
DPBS + 1% FCS + 1% P/S.12
Statistical analysis
Quantitative data were always expressed as mean±SEM.
Statistical comparison of values was performed using the Student’s
t-test. 
Results
A fraction of adult HSC derive from the G2-GATA4 
embryonic lineage
We analyzed the peripheral blood (PB) and bone marrow
of adult G2Cre;R26REYFP mice and investigated the presence of
YFP+ cells. After erythrocyte lysis, we found that about 20%
of leukocytes (CD45+), circulating monocytes (CD11b+), T
lymphocytes (CD3+) and B lymphocytes (B220+) in blood
samples were YFP+ (Figure 1A; Table 1).
In bone marrow samples, 20% of all the cells and 24% of
all the CD45+ cells were YFP+. Similar percentages were
found for B220+, CD11b+ and CD41+ cells. Erythroblasts
(Ter119+) and lymphocytes (CD3+, CD4/CD8+) or lymphoid
progenitors (CD127+, Online Supplementary Figure S1)
showed a lower and higher proportion of YFP+ cells, respec-
tively, but the differences were not significant. Similar pro-
portions of YFP+ cells were found in both the spleen and
thymus (Table 1). 
We then identified the bone marrow KSL population, i.e.,
cells expressing c-Kit and Sca1 but not lineage markers (Lin–,
defined as negative for CD3, Ly-6G/Ly-6C, CD11b, CD45R
and Ter-119). The KSL population constitutes about
0.075±0.02% of all the bone marrow cells and includes
hematopoietic stem and progenitor cells. 26,6±2,8% of the
bone marrow KSL cells were YFP+. The 1:4 proportion
between YFP+ and YFP– cells was also observed between the
CD135/Flk2– and CD135/Flk2+ KSL cells, representing long-
term and short-term HSCs, respectively (Table 1 and Figure
1B). Additionally we performed an experiment to estimate
the percentage of YFP+ cells within the bone marrow side
population identified by Hoechst 33342 staining.9 As shown
in Figure 1C, 18.5% of this side population was YFP+.
The presence of YFP+ cells in the bone marrow was con-
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firmed by confocal microscopy. We observed colocalization
of YFP with c-Kit and also with CD44, a marker present in
most hematopoietic cells (Figure 2A,B). 
About 30% of the SCA1+ cells from the bone marrow
were YFP+ (Table 1). Thus, we checked the colocalization of
YFP with other mesenchymal stem cell markers. We found
a relatively high percentage of YFP+ cells within the CD73+,
CD90+ and CD105+ Lin negative bone marrow populations,
reaching 30-40%. Furthermore, half of the
Lin–/Sca1+/PDGFRα+ population, enriched in mesenchymal
stem cells,13 was YFP+ (Online Supplementary Figure S2).
Thus, we cannot discard a contribution of the 
G2-Gata4 cell lineage to the bone marrow mesenchymal
stem cells. 
Finally, we checked the expression of GATA4 in the adult
bone marrow in order to disregard postnatal reactivation of
the G2 enhancer. Adult bone marrow cells do not express
GATA4 (Figure 1D).
G2Cre;R26REYFP bone marrow cells contain 
transplantable, long-term repopulating hematopoietic
stem cells  
2.5x106 bone marrow cells from G2Cre;R26REYFP mice were
injected in irradiated adult  recipient mice. About 20% of
the injected cells were derived from the G2-Gata4 lineage.
Multilineage contribution from YFP+ progenitors was deter-
mined at long-term (4 months posttransplantation) (Table
2). YFP+ cells were identified in peripheral blood, bone mar-
row and the spleen. In lysed peripheral blood, 17.7±6.2% of
all the cells were YFP+. This percentage was higher in the
cases of the T and B lymphocytes, reaching 25% for B220+
and 28% for the CD3+ population, respectively (Table 2). In
bone marrow, the proportion of YFP+ cells was well corre-
lated with that found in peripheral blood, reaching
14.4±8.0% of the total cells, again with a higher proportion
of CD3 lymphocytes (25%) and a lower fraction of ery-
throid cells (5.5%). The different contribution of YFP+ cells
to the CD3+ and Ter119+ populations was statistically signif-
icant (Student's t-test, P value=0.04). 
Hematopoietic progenitors, including HSCs, have been
shown to contribute to vascular endothelial cells in trans-
plantation assays.14 Therefore, we analyzed the distribution
of YFP+ cells in non-hematopoietic organs, such as the heart,
kidneys, lungs and liver. Most of the YFP+ cells found in
these organs expressed CD45 and were found close to the
walls of some vessels, probably indicating foci of
extramedullary hematopoiesis. A number of endothelial
(CD31+/CD45–) YFP+ cells were localized in the heart and
liver vessels, including the endocardium (Figure 2N-O). In
samples of lysed peripheral blood 28.4±9.1% (n=2) of the
CD45–/CD31+ cells were YFP+ (Online Supplementary Figure
S3). These cells could be putative circulating endothelial
progenitors.
We also tested the long-term multilineage repopulation
Adult HSC from GATA4 expressing embryonic lineage
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potential of bone marrow cells from G2Cre;R26REYFP mice by
performing transplantation into myeloablated newborn
mice, a model previously shown to allow hematopoietic
reconstitution by early embryonic as well as adult HSC
types.15 Busulfan-treated newborn mice received 5x106 bone
marrow cells (i.e., about 106 YFP+ cells). Peripheral blood
was analyzed one month (short-term) and 4-9 months
(long-term) after the transplant (Table 2). Out of 14 mice
transplanted, 8 showed YFP+cells in their peripheral blood,
with a mean percentage of YFP+ nucleated cells of
17.7±1.0% a month after the transplantation. This propor-
tion was similar in the long-term, and also in the bone mar-
row, thymus and spleen. No differences were found in the
proportion of YFP+/Ter119+ cells as compared with other
lineages. CD45+ cells showed similar percentages in the
long- and short-term, but YFP+ 
T lymphocytes were less represented in the blood samples
obtained in the short-term (7.6±1.6%) compared with the
long-term (14.4±2.8%). This difference was statistically sig-
nificant (Student's t-test, P value=0.03). In the long-term in
busulfan-treated chimaeras injected with bone marrow,
CD31+/CD45–/YFP+ endothelial cells were also detected in
the lungs and liver (data not shown). 
Hematopoietic progenitors from the G2-Gata4 lineage
are mainly localized in the placenta 
We performed a confocal microscopy study of the
embryonic hematopoietic tissues (AGM, placenta, fetal
liver) to study the distribution of the YFP+ cells (Figure 2C-
M). Most of the YFP+ cells located close to the aorta by
E10.5 are found in its dorsal part, around the notochord,
and they mainly represent sclerotome cells. A smaller pop-
ulation of YFP+ cells can also be seen in the mesentery and
ventral part of the aorta, sometimes in the aortic endotheli-
um (Figure 2C-E). Colocalization of YFP with CD31
demonstrated the endothelial nature of these cells (Figure
2C). YFP colocalizes with GATA4 protein in the mesotheli-
um of the periaortic area, suggesting that the enhancer G2
is activating Gata4 expression in these cells (Figure 2D).
Colocalization with RUNX1 also suggests that these YFP+
cells are hemogenic endothelium (Figure 2E). 
In the placenta, YFP+ cells are very abundant in the chori-
onic plate (Figure 2F-I), mainly around large vessels.
Colocalization of YFP with CD41 and CD31 was frequent.
Some YFP+ cells were observed apparently detaching from
the vascular endothelium (Figure 2G). As described for the
aorta, YFP+ cells also showed expression of GATA4 and
RUNX1, mainly in the vascular walls (Figure 2H,I).
However, YFP+ cells were GATA2-negative in the placenta
(Figure 2L). 
Finally, colocalization of YFP and GATA4 was very fre-
quent in the hepatic mesothelium and submesothelial areas.
As previously described,6 these cells represent mesothelial-
derived cells invading the liver to contribute to the hepatic
stroma (Figure 2J). Some of the YFP+ cells in the fetal liver
showed expression of endothelial and hematopoietic mark-
ers, including RUNX1 (Figure 2K) and GATA2 (Figure 2M). 
We performed several experiments to establish the
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Table 1. Frequency of YFP+ cells within different cell populations in G2Cre;R26REYFP mice.
Tissue All cells CD3 B220 CD45 CD11b Ter119 CD127 CD41 Sca1 KSL-
Peripheral blood Nº experiments 10 5 9 10 5
%  total cells 19.3±3.5 52.5±1.2 83.3±5.5 21.5±2.8
% YFP+ 17.7±2.1 21.2±5.8 20.1±2.0 18.8±1.5 20.3±1.8
Bone Marrow Nº experiments 17 6 6 16 2 14 2 7 4 6
% total 2.7±0.4 18.9±2.8 74.1±3.3 51,6±14,7 29.3±2.8 8.5±1.3 3.8±0.3 9.19±0.35 0.075±0.02
% YFP+ 19.9±1.1 26.4±4.9 25.1±3.5 24.1±1.6 24,6±0,54 19.1±2.4 23.1±0.9 24.9±2.4 30.4±0.66 26.6±2.8
Spleen Nº experiments 4 4 4 4 2
% total 26.3±0.6 52.5±8.6 24.3±9.9 15.2±1.2
% YFP+ 20.6±2.9 19.4±2.8 21.3±3.3 27.3±4.6 26.8±2.1
Thymus Nº experiments 4 4 2
% total 14.2±0.7 5.9±2.5
% YFP+ 18.9±2.9 19.2±1.9 19.8±0.8
The first row of each tissue (%  total cells) indicates the frequency of the population identified with each marker with respect to the total number of cells analyzed. The second
row (% YFP+) shows the proportion of YFP+ cells within each population (mean±SEM). KSL: c-Kit+/Sca1+/Lin–; Sca1: stem cell antigen 1.
Table 2. Frequency of YFP+ cells after transplantation of bone marrow from G2Cre;R26REYFP mice into irradiated adult mice and into busulfan-treated
newborns.
Peripheral blood Bone marrow Thymus Spleen
Total CD45 B220 T cells Total CD45 CD11b T cells Ter119 KSL Total Total
BM into irradiated 4 months 17.7±6,2 25.1±7.2 28.1±7.9 14.4±8.0 23.8±7.8 16.1±14.4 25.3±6.2a 5.5±3,4a 23.1±6.5
(CD3) (CD3)
BM into busulfan 1 month 17.7±1.0 17.3±1.1 7.6±1,6b
(CD4+CD8)
4-9 months 16.8±3.3 17.2±3.4 14.4±2,8b 14.6±2.7 15.3±2.9 17.1±3.6 14.2±2.8 13.4±2.6 18.6±4.5 16.0±5.6 16.2±2.2
(CD4+CD8) (CD4+CD8)
The table shows the frequency (%) of YFP+ cells in peripheral blood, bone marrow, the thymus and spleen after transplantation of bone marrow from G2Cre;R26REYFP mice into
irradiated adults (N=4) and into busulfan-treated newborns (N=8). Data represent mean±SEM.  aThe difference found between the % of YFP+ cells from the CD3 and the Ter119
populations was statistically significant (Student's t-test, P value=0.04). bThe difference found between the % of YFP+ cells in the CD4+CD8 populations in the short- and long-term
was statistically significant (Student's t-test, P value=0.03). BM: bone marrow; KSL: c-Kit+/Sca1+/Lin–.
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Figure 2. Localization of G2-GATA4 lineage cells (YFP+) in adult and embryonic tissues by confocal microscopy. A,B: YFP+ cells are localized in the bone marrow.
Some of these YFP+ cells express c-Kit (arrows in A, separate channels are shown in insert) and CD44 (arrows in B). C-E: YFP+ cells are also localized close to the
embryonic aorta (AO) by stage E10. YFP+ cells are abundant around the notochord (NC) and they are also observed in the dorsal mesentery (DM) and in the adjacent
coelomic epithelium (CE) (arrowhead in C). Some YFP+ cells can be seen in the aorta, expressing the endothelial marker CD31 (arrow in C). Expression of GATA4 is
prominent in the coelomic epithelium, suggesting activity of the enhancer G2 in specific areas of this tissue (D). Some YFP+ cells of the aortic endothelium are GATA4
immunoreactive (arrow and insert in D). The hematopoietic marker RUNX1 is expressed in some YFP+ cells of the aortic endothelium (arrows in E). F-I: YFP+ cells are
also abundant in the placenta at stage E12.5. A general view of the placenta (F) shows the distribution of the YFP+ cells, more abundant in the chorionic plate (CP)
and around the large vessels (V). The insert shows colocalization with the hematopoietic marker CD41 in the labyrinthine zone (LZ). YFP+ cells are very abundant in
the vascular walls, sometimes forming part of the CD31+ endothelium of the large vessels and apparently detaching from it (insert in G). Colocalization with GATA4
and RUNX1 was observed in the vascular walls (arrows in H,I). Note the population of cells expressing GATA4 without activation of the G2 enhancer (arrowhead in
H). J,K: YFP+ cells were also found in the fetal liver at stages E11.5 (J) and 13.5 (K). GATA4 is expressed by coelomic epithelium (CE) and mesenchymal cells of the
liver, and most of them are YFP+ (arrows in J). Some YFP+ cells also express the hematopoietic marker RUNX1 (arrows in K). L,M: Immunolocalization of GATA2 in the
placenta (L) and liver (M) of E11.5 and E12.5 embryos, respectively. No colocalization of GATA2 and YFP is evident in the placenta, but some YFP+ cells are GATA2+
cells in the liver (arrows) and others are not expressing GATA2 (arrowhead). N,O: YFP+ cells in the heart (N) and liver (O) of irradiated mice after four months of injec-
tions of bone marrow cells from G2Cre;R26REYFP mice. A number of these cells express the endothelial marker CD31 but they are negative for CD45. Some of these
cells are integrated in the endocardium (EN). Clusters of hematopoietic cells appear in the wall of some hepatic sinusoids (arrow in O). P,Q: Busulfan-treated mice
injected with cells obtained from G2Cre;R26REYFP embryos. After 4-7 months, putative endothelial CD31+/CD45–/YFP+ cells can be seen in the liver after injection of
aorta-gonad-mesonephros (P) and placental (Q) cells (arrows). Bars represent 33 μm except for F (200 μm), L (50 μm) and M (25 μm). The images were acquired
as 3-channel images by a Leica SP5 II confocal microscope (Leica, Heidelberg, Germany) using LAS AF software and 40X and 63X oil immersion objectives (numerical
apertures 1.35 and 1.40, respectively). Levels were adjusted for the entire images using Photoshop 8.0.1. 
embryonic origin of the HSCs of the G2-Gata4 lineage. The
cells used for these experiments were obtained from the
fetal liver, AGM, placenta and yolk sac of E11.5
G2Cre;R26REYFP embryos, when definitive HSCs have already
emerged.16 We considered two criteria to identify the fetal
hematopoietic progenitors: CD41+/cKit+/CD34+ and
Lin–/cKit+/CD31+.17,18 The four embryonic organs examined
contained a population of YFP+ cells in all the stages studied,
but the highest absolute and relative numbers of
CD41+/cKit+/CD34+/YFP+ cells were found in the placenta
(Table 3 and Online Supplementary Figure S4). The
Lin–/cKit+/CD31+/YFP+ cells were also relatively abundant in
the placenta, while they were virtually absent from the
AGM region, where Lin–/cKit+/CD31+/YFP– cells were more
frequent (Table 3 and Online Supplementary Figure S4). 
We have assayed the potential of the G2Cre;R26REYFP cells
isolated from hematopoietic tissues of E10-E11 embryos to
form hematopoietic colonies in the MethoCult assay. In
three independent experiments, and seeding five plates by
organ (10000 cells in each experiment), the cells obtained
from fetal liver exhibited the highest clonogenic ability
(Table 4). 29.2% of them were YFP+. Interestingly, the pla-
centa showed a higher potential than the AGM to form
colonies in vitro, and most (81.3%) of these placenta-derived
colonies were YFP+ versus only 20% of the AGM-derived
colonies. Thus, YFP+ colony forming cells are far more abun-
dant in the placenta than in the AGM region. Furthermore,
the culture of ten E8 ectoplacental cones in MethoCult also
gave rise in one case to four YFP+ colonies, suggesting that
G2-Gata4 hematopoietic progenitors are present in the
early placenta, even before the onset of circulation.
In order to directly compare the hematopoietic potential
of the G2-Gata4 lineage cells obtained from different
organs, we isolated the YFP+ fraction from each organ
through fluorescence-activated cell sorting (FACS, E11.5
and E12.5) and seeded the purified cells in MethoCult. The
result of three experiments is shown in Table 4. Fetal liver
contained the highest number of YFP+ colony-forming cells,
followed by the placenta. However, only a few colonies
were obtained when the same numbers of YFP+ cells isolat-
ed from the AGM region were cultured.  
We next checked the potential of the embryonic 
G2-Gata4 lineage cells to repopulate the adult hematopoiet-
ic system, using the busulfan-treated newborn mouse
model. We transplanted AGM, fetal liver and placental cells
from stages E11.5-E12.5, as well as purified YFP+ cells sorted
from the same tissues (Table 5). After four weeks we
observed that the level of reconstitution of the hematopoi-
etic system, as assessed by the percentage of YFP+ cells in
peripheral blood, was similar when AGM, fetal liver and
placental cells were injected in the newborn mice, between
6.7% (placenta) and 11.0% (fetal liver). This percentage
reached 19.2% in the AGM-injected chimaeras after 4-9
months, but the increase was small or absent in the chi-
maeras injected with placental or liver cells. The percent-
ages of YFP+ cells in the bone marrow, thymus and spleen
were similar in all the experiments. 
A significant difference between the short-term and long-
term reconstitution of the T-lymphoid compartment was
observed (Table 5), as described above for the busulfan-
treated mice injected with adult bone marrow. The percent-
age of YFP+ T lymphocytes increased between the short-
and long-term independently of the origin of the cells.
Considering all the experiments, the frequency of the YFP+
lymphocytes increased three times, from 4% to 12%
(Student's t-test, P value=0.015), while the increase of the
CD45+/YFP+ cells was not significant. 
When busulfan-treated newborns were injected with
YFP+ cells purified by FACS from the three embryonic tis-
sues, the fetal liver showed the highest ability to reconsti-
tute the hematopoietic system, followed again by the pla-
cental cells (Table 6). YFP+ cells isolated from the AGM
region showed a very weak ability to reconstitute the
hematopoietic system in these mice, never reaching >1% of
the nucleated blood cells. Thus, YFP+ cells from the placenta
showed a much higher short- and long-term reconstitution
potential than YFP+ cells isolated from the AGM region. In
these mice, we again observed a statistically significant dif-
ference between short- and long-term percentages of lym-
phoid YFP+ cells (Table 6).
We also analyzed the contribution of YFP+ cells to non-
hematopoietic organs in the long-term busulfan-treated chi-
maeras injected with embryonic tissues. Endothelial cells of
the G2-Gata4 lineage can be seen in many organs, and they
were more abundant in the liver sinusoids (Figure 2P,Q).
GATA4 is not directly involved in the differentiation of
hematopoietic progenitors
To ascertain if GATA4 is required for embryonic
hematopoiesis we have studied the conditional deletion of
GATA4 in Scl-expressing cells (SCLCreERT;Gata4flox/flox).
When GATA4 is deleted in the cells of the G2-Gata4 line-
age, mice develop anemia.6 We inactivated GATA4 in cells
of the SCL lineage through tamoxifen induction at different
stages (E9.5-E11.5), but no differences were observed in the
fetal hematopoiesis at different ages (E12.5-E14.5) (Online
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Table 3. Absolute and relative number of  HSCs/YFP+ cells found in hematopoietic embryonic tissues.
Total number 
of cells/tissue % of CD41+ CD34+cKit+ Estimated number  % of LIN–CD31+cKit+ Estimated number of
Tissue E11-5 (x10000) cells within of CD41+ CD34+ cells cells within the P1 gate LIN–CD31+cKit+ cells
(n=5) the P1 gate (n=4) by organ (n=4) (n=3) by organ (n=3)
YFP+ YFP– YFP+ YFP– YFP+ YFP– YFP+ YFP–
Fetal liver 27.2±14.7 0.29±0.03 2.29±0.88 514±193 3813±996 0,45±0,17 12.56±1.96 1016±607 26689±4235
(n=3) (n=3) (n=3) (n=3)
AGM 21±5,6 0.02±0.01 0.07±0.02 29±13 108±31 0.003±0.003 0.12±0.07 11±8 181±104
Placenta 379.2±83.2 0.90±0.21 2.55±0.64 2508±363 7151±1531 0.14±0.05 1.19±0.45 359±163 3322±2367
YS 100 0.32±0.12 0.27±0.07 1297±470 1099±197 0.13±0.07 0.83±0.47 479±208 3096±1316
The table shows the estimated absolute and relative number of YFP+ and YFP– hematopoietic progenitors (defined by two criteria: cKit+/CD41+/CD34+ and cKit+/CD31+/Lin–) in
different embryonic tissues (mean±SEM). The number of cells in the yolk sac is an estimation based on our previous work. HSCs: hematopoietic stem cells; AGM: aorta-gonad-
mesonephros: YS: yolk sac. 
Supplementary Table S2). 
Discussion
Early embryonic hematopoiesis occurs in three main ter-
ritories; the yolk sac, AGM region and placenta. It has been
well established that the hematopoietic progenitors origi-
nated in the yolk sac give rise to a transient wave of blood
cells, mainly erythroid. Moreover, definitive HSCs are con-
sidered to derive from the AGM region, since the role
played by the placenta in definitive hematopoiesis is more
controversial, as discussed below. The lack of markers
allowing one to distinguish between placental and intraem-
bryonic HSCs has hampered the solving of this controversy.  
We have identified two distinct lineages in the adult
blood cells of mice, characterized by the activity, during
embryonic life, of an enhancer of the Gata4 gene 
(G2-Gata4) that drives its expression in the allantois/placen-
ta and lateral mesoderm, starting at E7.5 and ceasing by
midgestation. About 20% of the murine adult blood cells
belong to this lineage, and this percentage shows a remark-
able consistency between individuals. The G2-Gata4 line-
age of blood cells derive from bone marrow HSCs which
can be transplanted and reconstitute, over the long-term,
the hematopoietic system of both lethally irradiated and
busulfan-treated mice. The HSCs belonging to the G2-
Gata4 lineage give rise to all kinds of blood cells and even
to putative circulating endothelial progenitors and long-
term engrafted vascular endothelial cells, and they show
basically the same properties as the other HSCs. An excep-
tion was the lower percentages of YFP+ T lymphocytes
found in the short-term reconstitution of the hematopoietic
system after myeloablation. This difference might be
explained by the persistence of the host lymphocytes after
the transplantation. T lymphocytes half-life in humans span
for weeks,19 thus, host lymphocytes of myeloablated mice
are probably diluting the YFP+ lymphocytes in the  short-
term and reducing their relative abundances. On the other
hand, the smaller frequency of YFP+ cells found among the
Ter119+ bone marrow population can be explained by
downregulation of the expression of YFP as the erythrob-
lasts differentiate. 
The existence of heterogeneity among populations of
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Table 4. Number of colonies generated in MethoCult after seeding of embryonic cells from different origins.
Type of cells Tissue Stage Number of colonies Analyzed by cytospin YFP+ colonies
Total Fetal liver E10-11 88.4±4.8 65 19 (29,2%)
Total AGM E10-11 1.7±0.89 10 2 (20%)
Total Placenta E10-11 3.4±1.0 16 13 (81,3%)
YFP+ purified Fetal liver E11,5 55.9±7.3
YFP+ purified Fetal liver E12,5 44.3±6.7
YFP+ purified AGM E11,5 0.33±0.12
YFP+ purified AGM E12,5 0.1±0.058
YFP+ purified Placenta E11,5 5.7±0.64
YFP+ purified Placenta E12,5 1.0±0.38
The number of colonies generated in MethoCult after seeding of cells obtained from three hematopoietic tissues is presented. 10000 total cells were obtained from the tissues
(E10-11, N=5) or 2000-14000 YFP+ cells were purified for each tissue (N=3, results are normalized to 1000 cells). In both cases the cells were seeded and the number of colonies
counted. In the case of total cells seeded, the frequency of the YFP+ colonies was analyzed by cytospin (mean±SEM).  AGM: aorta-gonad-mesonephros.
Table 5. Frequency of YFP+ cells after transplant of embryonic cells in busulfan-treated newborns.
Analyzed tissue Donor tissue Term All cells CD45 CD4+CD8a Ter119 KSL
Peripheral blood Fetal liver ST 11.0±2.1 (2) 10.7±2.3 (2) 5.1±0.78 (2)
AGM ST 8.4±0.57 (6) 10.1±1.4 (5) 1.8±0.61 (6)
Placenta ST 6.7±0.45 (4) 6.5±0.6 (4) 5.3±2.9 (4)
Fetal liver LT 10.7±4.5 (2) 10.8±4.5 (2) 11.6±4.7 (2)
AGM LT 19.2±4.5 (6) 18.4±6.2 (6) 14.1±4.0 (6)
Placenta LT 8.2±3.6 (4) 8.5±3.8 (4) 7.9±5.5 (4)
Bone marrow Fetal liver LT 10.7±7.4 (2) 11.0±10.5  (2) 27.6 (1)b 10.5±11.3  (2) 11.7±9.7  (2)
AGM LT 16.7±6.4 (6) 22.8±24.6 (6) 17.2±18.9 (4)b 17.1±10.7 (6) 16.8±6.1 (6)
Placenta LT 18.5±17.1 (4) 18.6±33.9 (4) 24.3±30.4 (2)b 18.5±32.0 (4) 25.4±21.1 (4)
Thymus Fetal liver LT 26.6 (1)
AGM LT 29.4±16.4 (4)
Placenta LT 20.1±18.9 (2)
Spleen Fetal liver LT 17.0 (1)
AGM LT 16.3±7.4 (4)
Placenta LT 17.5±8.3 (2)
The table shows the frequency of YFP+ cells (mean±SEM) in peripheral blood in the short- and long-term (1 and 4-9 months, respectively), bone marrow, the thymus and spleen
(only long-term) after transplantation of cells from G2Cre;R26REYFP embryos into busulfan-treated newborns. The number of experiments is between parentheses. aThe difference
found between the % of YFP+ cells in the CD4+CD8 populations in the short- and long-term was statistically significant when the experiments were gathered  (ST: 4.1±1.2%, LT:
11.8±2.6%, Student's t-test, P value=0.015). bCD3 was used instead of CD4+CD8 in these samples. AGM: aorta-gonad-mesonephros; ST: short-term; LT: long-term; KSL: c-Kit+/Sca1+/Lin–.   
adult HSCs has been well established, but their causes and
their potential relationships with different pathways of
developmental hematopoiesis are unknown.20-23 As acknowl-
edged by Kaimakis et al., the hematopoietic progenitors gen-
erated in the embryo result as being more diverse than pre-
viously appreciated.24 These authors described a population
of embryonic hematopoietic progenitors cells (HPCs) that
did not express GATA2, and they suggested that GATA4 is
expressed and might play some role in this specific popula-
tion. This proposal might be related with our observation of
a lineage of HSCs derived from GATA4 expressing progeni-
tors. In fact, we found no expression of GATA2 in the YFP+
cells from the placenta, although part of the fetal liver YFP+
cells  were GATA2+ (Figure 2L,M). Thus, we do not disregard
that the G2-Gata4 hematopoietic lineage can overlap totally
or partially with the already described GATA2-independent
population of HPCs.24 
An important point revealed in our study is the embryon-
ic origin of the G2-Gata4 HSCs. The G2 enhancer activates
GATA4 expression in hematopoietic cells from both the
placenta and AGM, although YFP+ cells were far more
abundant in the placenta. The yolk sac also showed a sig-
nificant population of presumptive YFP+ hematopoietic pro-
genitors, but they probably do not originate in the yolk sac,
since the enhancer G2 is not driving GATA4 expression in
that tissue.5 In fact, conditional deletion of GATA4 in the G2
domain does not cause abnormalities in the yolk sac.6 Thus,
we compared the number of YFP+ hematopoietic progeni-
tors identified under two different criteria,
(CD41+/cKit+/CD34+ and Lin–/CD31+/cKit+),17,18 in the pla-
centa and in the AGM, and they were much more abundant
in the former. In fact, Lin-/CD31+/cKit+/YFP+ cells were vir-
tually lacking in the AGM region, whereas a significant
number of Lin–/CD31+/cKit+/YFP– cells were identified. YFP+
colonies were four times more frequent in MethoCult
when we seeded placental cells than when AGM cells were
seeded. When unfractionated AGM and placental cells
were transplanted into busulfan-treated newborn mice, the
contribution to the YFP+ blood cells was basically similar.
Interestingly, we recorded a two-fold increase of the AGM
contribution to the reconstituted YFP+ population in periph-
eral blood in the long-term as compared with the short-
term, although this increase was not significant and it was
not evident in bone marrow. Furthermore, YFP+ cells from
the placenta, but not those isolated from AGM, reconstitut-
ed the hematopoietic system of busulfan-treated newborns.
We cannot exclude that YFP+ cells from the AGM require
accessory cells for engraftment and/or a process of matura-
tion and expansion to acquire a potential of reconstitution
similar to that exhibited by the placental YFP+ cells.25
However, we think that our experimental evidence clearly
supports a placental origin for most YFP+ hematopoietic
progenitors, and presumably also for most of the adult
HSCs derived from the G2-Gata4 lineage. 
Placental hematopoiesis has been well described,16,26-27
although the primary origin of placental HSCs is controver-
sial.28 The allantois from embryos E8 pre-cultured in toto
prior to seeding in a semisolid medium has demonstrated
containing hematopoietic potential.29 Using this experimen-
tal system, we performed the MethoCult assay with ecto-
placental cones and allantois by E8, before the onset of the
circulation, and have obtained YFP+ colonies in one case.
This supports the ability of the placenta to generate defini-
tive HSCs, as suggested by other reports.30
To date, there is no report of GATA4 being involved in
hematopoiesis. We previously suggested that the anemia
phenotype found in mouse embryos with conditional dele-
tion of GATA4 in the lateral mesoderm domain was due to
the failure of the expansion of hematopoietic progenitors in
the liver, rather than from a direct impact of a lack of
GATA4 in hematopoietic cells.6 Our new results confirm
this idea, as no hematopoietic defects were found when we
inactivated Gata4 either in the G2-GATA4 lineage, or in the
hematopoietic progenitors using an inducible SclCreERT
driver. However, redundancy among members of the
GATA family have been previously described,31-34 and we
have discussed above how Kaimakis et al. do not disregard
some redundancy between GATA4 and GATA2 in a sub-
population of embryonic hematopoietic progenitors cells.24 
The embryonic origin of the different populations of
bone marrow mesenchymal stem cells is still poorly
known.35,36 This was not an aim of our study, but we
observed a contribution of YFP+ cells to the lineage-negative
bone marrow cells within the CD90+, CD73+ and CD105+
subpopulations, classical markers of mesenchymal stem
cells. This contribution was higher (30-40%) than that
obtained for hematopoietic stem cells. Furthermore, 50% of
the lineage-negative SCA1+/PDGFRα+ population, that is
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Table 6. Frequency of YFP+ cells after transplant of YFP+ cells purified from embryonic tissues in busulfan-treated newborns.
Donor tissue Number Survivors Mice Mice
and number of with with Bone
of YFP+ cells transplants >1%  >1% marrow Thymus Spleen
transplanted YFP+ YFP+ Lysated PB
ST LT All cells    CD4+CD8a CD45 B220 CD11b All All All
cells cells cells
ST LT ST LT ST LT LT LT LT LT LT
Fetal liver (20000 cells) 4 4 2 2 26.0± 55,6± 19.6± 70.9± 31.7± 55.6± 68.1± 47.8± 60.3± 90.8± 76.4±
4.1 12.7 6.6 4.1 6.0 5.0 4.7 9.1 10.6 0.78 2.8
AGM (10000-25000 cells) 6 4b 0 0 - - - - - - - - - - -
Placenta (13000-25000 cells) 9 7 4 3 19.9± 43.5± 7.7± 40.9± 19.8± 42.9± 46.8± 54.3± 43.6± 62.6± 47.7±
10.3 26.1 4.7 24.6 10.6 25.6 28.8 33.2 23.5 31.3 20.9
The table shows the frequency of YFP+ cells (mean±SEM) in peripheral blood in the short- and long-term (ST and LT, 1 and 4-9 months, respectively), bone marrow, the thymus and
spleen  after transplantation  into busulfan-treated newborns of YFP+ cells purified from tissues from G2Cre;R26REYFP embryos. aThe difference found between the % of YFP+ cells in the
CD4+CD8 populations in the short- and long-term was statistically significant when the experiments were gathered  (ST: 12.4±4.1%, LT: 52.9±13.3%, Student's t-test, P value=0.036). bThe
percentages of YFP+ cells found in these mice were between 0.01% and 0.47%.  AGM: aorta-gonad-mesonephros; ST: short-term; LT: long-term; PB: peripheral blood.
enriched in mesenchymal stem cells,13 was also YFP+.
Further study would be necessary to establish the relevance
of these observations, possibly related to the origin of a
mesenchymal stem cell subpopulation from the lateral
mesoderm.       
In summary, we have identified a distinct lineage of adult
HSCs characterized by its derivation of progenitors where
Gata4 expression is activated by a specific enhancer. Most
adult HSCs belonging to this lineage probably originate in
the placenta. Despite the relatively normal behavior of this
specific lineage, further experiments would be required to
examine whether they exhibit differences in response to
different physiopathological conditions.
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